Latest Market Access News

James Hardie Industries has completed its $8.4 billion acquisition of The AZEK Company, creating a powerhouse in exterior home and outdoor living solutions. The merger promises accelerated growth, significant synergies, and a broadened global footprint.

Findi Limited’s shares have been suspended from trading on the ASX starting 1 July 2025 due to failure to lodge a required periodic report on time. The suspension will remain until the report is submitted and trading can resume.

New Murchison Gold Limited has secured all key approvals and mobilised equipment for mining at its Crown Prince Gold Project, with first ore delivery expected by September 2025. The company also announced a $15 million capital raise to support its transition from explorer to producer.

AIC Mines has locked in a US$40 million prepayment facility tied to a copper offtake agreement with Trafigura, aiming to boost processing capacity at its Eloise mine.

New World Resources Limited has had its trading suspension lifted immediately following a key announcement, reopening market access for investors.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.

Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.

Top End Energy updates its Northern Territory exploration strategy amid record gas flow tests in the Beetaloo Basin, signaling a shift from appraisal to development.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.

Clara Resources Australia Ltd has had its trading suspension lifted following a capital raising announcement, signaling renewed market activity for the mining company.

Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.